Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. M...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez Rovira, Pedro, Seguí, M. A., Llombart, A., Aranda, Enrique, Antón, Antonio, Sánchez, A., Lomas, M., Jaén, A., Fernández, M., Porras, I., Dalmau, E., Morales Murillo, Serafín, Haba-Rodríguez, J. de la
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2013
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/70819
Acceso en línea:https://doi.org/10.1007/s12094-013-1006-4
http://hdl.handle.net/10459.1/70819
Access Level:acceso abierto
Palabra clave:Bevacizumab
Biomarkers
Breast cancer
Combined modality therapy
Neoadjuvant therapy
id ES_b104bf36eca18e2b0f31f91c74295a97
oai_identifier_str oai:recercat.cat:10459.1/70819
network_acronym_str ES
network_name_str España
repository_id_str
spelling Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic responseSánchez Rovira, PedroSeguí, M. A.Llombart, A.Aranda, EnriqueAntón, AntonioSánchez, A.Lomas, M.Jaén, A.Fernández, M.Porras, I.Dalmau, E.Morales Murillo, SerafínHaba-Rodríguez, J. de laBevacizumabBiomarkersBreast cancerCombined modality therapyNeoadjuvant therapyPurpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. Methods: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment. Results: Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed. Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials.Financial support for this research was provided by Roche Farma, S.A.Springer202120212013info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1007/s12094-013-1006-4http://hdl.handle.net/10459.1/70819http://hdl.handle.net/10459.1/70819reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a https://doi.org/10.1007/s12094-013-1006-4Clinical & Translational Oncology, 2013, vol. 15, núm. 10, p. 810-817cc-by (c) Sánchez-Rovira et al., 2013info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:recercat.cat:10459.1/708192026-05-29T05:05:01Z
dc.title.none.fl_str_mv Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
title Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
spellingShingle Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
Sánchez Rovira, Pedro
Bevacizumab
Biomarkers
Breast cancer
Combined modality therapy
Neoadjuvant therapy
title_short Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
title_full Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
title_fullStr Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
title_full_unstemmed Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
title_sort Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
dc.creator.none.fl_str_mv Sánchez Rovira, Pedro
Seguí, M. A.
Llombart, A.
Aranda, Enrique
Antón, Antonio
Sánchez, A.
Lomas, M.
Jaén, A.
Fernández, M.
Porras, I.
Dalmau, E.
Morales Murillo, Serafín
Haba-Rodríguez, J. de la
author Sánchez Rovira, Pedro
author_facet Sánchez Rovira, Pedro
Seguí, M. A.
Llombart, A.
Aranda, Enrique
Antón, Antonio
Sánchez, A.
Lomas, M.
Jaén, A.
Fernández, M.
Porras, I.
Dalmau, E.
Morales Murillo, Serafín
Haba-Rodríguez, J. de la
author_role author
author2 Seguí, M. A.
Llombart, A.
Aranda, Enrique
Antón, Antonio
Sánchez, A.
Lomas, M.
Jaén, A.
Fernández, M.
Porras, I.
Dalmau, E.
Morales Murillo, Serafín
Haba-Rodríguez, J. de la
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Bevacizumab
Biomarkers
Breast cancer
Combined modality therapy
Neoadjuvant therapy
topic Bevacizumab
Biomarkers
Breast cancer
Combined modality therapy
Neoadjuvant therapy
description Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. Methods: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment. Results: Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed. Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials.
publishDate 2013
dc.date.none.fl_str_mv 2013
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1007/s12094-013-1006-4
http://hdl.handle.net/10459.1/70819
http://hdl.handle.net/10459.1/70819
url https://doi.org/10.1007/s12094-013-1006-4
http://hdl.handle.net/10459.1/70819
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1007/s12094-013-1006-4
Clinical & Translational Oncology, 2013, vol. 15, núm. 10, p. 810-817
dc.rights.none.fl_str_mv cc-by (c) Sánchez-Rovira et al., 2013
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Sánchez-Rovira et al., 2013
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416875494998016
score 15.812455

Similares en LA Referencia